Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|June 22, 2010
Reliable Detection and Quantification of Protein Impurities
Automatic and reliable detection and quantification of low concentrated protein impurities down to 0.05% and below with the Agilent 2100 Bioanalyzer!
Advertisement
The Agilent 2100 Bioanalyzer provides:
- sensitivity and linear dynamic range – silver stain sensitivity down to 1 pg/μL of labeled protein on chip and 4 orders of magnitude in linear dynamic range
- fast results – complete automated analysis of 10 samples in 30 minutes
- reproducibility – qualitative, user-independent and digital data
- ease of use – standardized assay, pre-packaged reagent kits
- 21 CFR Part 11 compliance – validated reagents and software plus Agilent compliance services to meet all GMP/GLP needs.
The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is suited excellent to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines – in the Bioanalyzer-like, fast and reproducible way.Learn more!
Contact:
Agilent Technologies, Inc.
Life Sciences and Chemical Analysis Group
5301 Stevens Creek Boulevard
Santa Clara, CA 95051-7201
USA
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement